For the second quarter of fiscal year 2023, TRANSMEDICS GROUP ($NASDAQ:TMDX) recorded a total revenue of USD 52.5 million and a net income of USD -1.0 million. Compared to the same quarter in the previous year, the revenue increased by 155.7%, while the net income decreased by 11.52 million.
On Thursday, TRANSMEDICS GROUP reported its total revenue for the second quarter of fiscal year 2023, at USD 52.5 million. The net income for the period was reported at USD -1.0 million, indicating a decline from the previous quarter’s income. On the same day, the stock opened at $87.2 and closed at $87.5, down by 0.6% from the previous closing price of 88.1. The company is also facing difficulty in executing its strategic plans as it adjusts to increased demand for its products. In an attempt to improve its earnings, TRANSMEDICS GROUP has launched several initiatives, including introducing new products and increasing its focus on digital marketing efforts.
The company has also announced a plan to invest additional resources in research and development activities to expand its product portfolio and increase customer satisfaction. Despite the quarterly decline in profits, TRANSMEDICS GROUP remains confident in its outlook and continues to focus on long-term growth opportunities while optimizing operational performance and cost savings. The company is optimistic that its initiatives and investments will help drive future growth and profitability. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Transmedics Group. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Transmedics Group. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Transmedics Group. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Transmedics Group are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of TRANSMEDICS GROUP‘s fundamentals. Our Risk Rating shows that TRANSMEDICS GROUP is a medium risk investment in terms of both the financial and business aspects. We detected 3 risk warnings in the income sheet, balance sheet, and cashflow statement. If you are interested in learning more about these risk warnings, sign up to become a registered user on our platform to gain access to our exclusive content. Our platform is designed to help you make informed investment decisions by providing tailored insights into the financial health of the companies you are considering investing in. More…
Risk Rating Analysis
Star Chart Analysis
The company’s primary competitors are RxSight Inc, Motus GI Holdings Inc, Lucid Diagnostics Inc. All these companies are engaged in the development of technologies that would improve the outcomes of organ transplantation. While TransMedics Group Inc has a strong position in the market, its competitors are also gaining ground.
RxSight Inc. is a medical device company that develops and markets advanced artificial intelligence and machine learning software for the treatment of eye diseases. The company’s products are used by ophthalmologists and optometrists to improve patient outcomes and reduce costs. RxSight Inc. is headquartered in Irvine, California.
– Motus GI Holdings Inc ($NASDAQ:MOTS)
Motus GI Holdings Inc is a medical technology company that develops and commercializes gastrointestinal products. The company’s primary product is the Full Spectrum Endoscopy (FSE) system, which is a next-generation platform that provides improved visualization of the GI tract. Motus GI Holdings Inc also offers the CleanCide Wipe, a sanitizing product for endoscopes. The company has a market cap of 6.17M and a ROE of -183.03%.
– Lucid Diagnostics Inc ($NASDAQ:LUCD)
Lucid Diagnostics Inc is a medical diagnostic company that develops and commercializes proprietary technologies to provide clinicians with actionable information at the point of care. The company’s products include the Lucid Reader, a handheld device that delivers rapid and accurate results for a variety of common diagnostic tests; and the Lucid IQ, a cloud-based software platform that aggregates and analyzes data from multiple sources to provide real-time insights into patient health. Lucid Diagnostics Inc has a market cap of 72.12M as of 2022 and a Return on Equity of -67.45%.
Investors should be encouraged by TRANSMEDICS GROUP‘s reported total revenue of USD 52.5 million and net income of USD -1.0 million for their second quarter of FY2023, ending on June 30 2023. Total revenue increased by 155.7% compared to the same quarter the previous year, while net income improved by -11.52 million. This indicates the company is growing significantly and is on track to achieve its financial goals. It is important to note, however, that with a negative net income, the company’s financial health may be of concern and further research before investing is recommended.